## Nasdaq Regulation



William Slattery, CFA Vice President Listing Qualifications

## Electronic Mail Only

June 1, 2020

Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549

## Division of Corporate Finance:

This is to certify that on May 29, 2020, The Nasdaq Stock Market (the "Exchange") received from Pliant Therapeutics, Inc. (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following securities:

Common Stock, \$0.0001 par value per share

We further certify that the securities described above have been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking effectiveness of the Form 8-A 12(b) concurrently with effectiveness of its 1933 Act Registration Statement, and we hereby join in such request.

Sincerely,

William Lattery